


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+9.65%
-1.15%
-16.03%
+3.58%
-16.49%
HUMA
Humacyte
$1.22
Strengths

Upgraded on attractively valued
Risk Analysis

Earnings are forecast to decrease
HUMA Price Performance
$1.17 (+4.27%)
$1.29 (-5.43%)
$1.53 (-20.26%)
$3.22 (-62.11%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
Analysts perspectives on the stock desirability, trend direction and growth potential
HUMA has Extreme risk level
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Dec 23, 2025
Reiterate
Buy
D. Boral Capital
Nov 21, 2025
Reiterate
Buy
BTIG
Nov 21, 2025
Reiterate
Buy
D. Boral Capital
Nov 14, 2025
Reiterate
Buy
Benchmark
Nov 13, 2025
Reiterate
Buy
D. Boral Capital
What is HUMA current stock price?
What are HUMA stock strengths?
What is HUMA Risk Level?
What is HUMA market cap and volume?
What is HUMA current Stock IQ?
Should I buy HUMA stock right now?
Is HUMA a Strong Buy right now?
What does a 'Strong Buy' rating mean for HUMA?
What does a 'Strong Sell' rating mean for HUMA?
What factors influence HUMA's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.65%
-1.15%
-16.03%
+3.58%
-16.49%
HUMA
Humacyte
Current Price
$1.22

HUMA Price Performance
$1.17 (+4.27%)
$1.29 (-5.43%)
$1.53 (-20.26%)
$3.22 (-62.11%)
HUMA Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
Analysts perspectives on the stock desirability, trend direction and growth potential
HUMA has Extreme risk level
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Dec 23, 2025
Reiterate
Buy
D. Boral Capital
Nov 21, 2025
Reiterate
Buy
BTIG
Nov 21, 2025
Reiterate
Buy
D. Boral Capital
Nov 14, 2025
Reiterate
Buy
Benchmark
Nov 13, 2025
Reiterate
Buy
D. Boral Capital
HUMA Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued
Risk Analysis

Earnings are forecast to decrease
HUMA Latest Analysis
Humacyte: Positive News For Symvess At Last But Long-Term Threats Persist.
Today
Humacyte jumps as United States legislation backs bioengineered vessels.
Today
Humacyte Announces New United States Department of Defense Funding for Procurement of Bioengineered Blood Vessels. DURHAM N.C. Feb. 09 2026 (GLOBE NEWSWIRE) -- Humacyte Inc. (Nasdaq: HUMA) a commercial-stage biotechnology platform company developing universally implantable bioengineered human tissues at commercial scale today announced that the recently adopted FY 2026 United States Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporat
Today
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
HUMA Stock trends
HUMA Stock performance
HUMA Stock analysis
HUMA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.